Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Experts having hissy fits
View:
Post by retiredcop on Jun 11, 2021 9:47am

Experts having hissy fits

There is a saying " when you think your the smartest person in the room , best to leave the room"  That can create a problem with people that have the label of " EXPERT" . This wont be the first or last time this happens. I wonder how much money they are giving up to be on the advisory board and is it a political appointment.  Proabably not going to find someone that wants to take the position.
Comment by Thenorth1990 on Jun 11, 2021 2:50pm
It's quite confusing because a lot of people who participated in the trials have mentioned the benefits and on the other side biogen proceeded with this application without fully completing these trials and that just demerits the whole regulatory process from a public outlook I guess.
Comment by retiredcop on Jun 11, 2021 5:26pm
Actually the problem was that biogen and FDA were the only ones who had access to the the additional info and thats helped the FDA makes their decision. Alot of the upper management and scientists at PMN and some of these other companies knew there was more data that others were not seeing ( including them), and were pretty sure that if FDA approved  Biogen there were going to be way more ...more  
Comment by Thenorth1990 on Jun 11, 2021 5:43pm
Agreed
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities